Pharmaceutical Companies Poised to Build Infrastructure to Accommodate Real World Evidence, According to the Tufts Center for the Study of Drug Development

BOSTON, MA -- (Marketwired) -- 11/08/17 -- Real world evidence is poised to play a growing…

Continue Reading

Cardiovascular Drug Approval Rate in the U.S. Fell as Development Time Rose, According to the Tufts Center for the Study of Drug Development

BOSTON, MA -- (Marketwired) -- 09/12/17 -- Although the rate at which investigational drugs received marketing…

Continue Reading

Abuse-Deterrent Opioid Development and Uptake Are Tied to Efficacy and Regulatory/Payer Policies, According to the Tufts Center for the Study of Drug Development

BOSTON, MA -- (Marketwired) -- 07/13/17 -- Although 10 new opioid products with abuse-deterrent formulations (ADF)…

Continue Reading

Accelerating Pace of Approvals and a Strong Development Pipeline Indicate Vigorous Growth for New Biotech Products, According to the Tufts Center for the Study of Drug Development

BOSTON, MA -- (Marketwired) -- 05/09/17 -- Biopharmaceuticals accounted for 35% of all new drug approvals…

Continue Reading

Ritter Pharmaceuticals Appoints William Merino, Ph.D., to its Board of Directors

LOS ANGELES, CA -- (Marketwired) -- 01/17/17 -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or…

Continue Reading

Poor Physician and Nurse Engagement Contributes to Low Patient Recruitment Rates, According to the Tufts Center for the Study of Drug Development

BOSTON, MA -- (Marketwired) -- 01/11/17 -- Although physicians and nurses are familiar with, and comfortable…

Continue Reading

Cost to Develop and Win Marketing Approval for a New Drug Is $2.6 Billion, According to the Tufts Center for the Study of Drug Development

BOSTON, MA -- (Marketwired) -- 11/18/14 -- Developing a new prescription medicine that gains marketing approval,…

Continue Reading

ADVISORY – Tufts CSDD to Disclose Cost of Developing a New Drug at Nov. 18 Briefing

BOSTON, MA -- (Marketwired) -- 11/10/14 --Tufts Center for the Study of Drug Development, Tufts University,…

Continue Reading

Global Holdings, Inc. (GBHD) Obtains Exclusive Rights to a Patent-Pending Pharmaceutical Treatment of Endometriosis

VIRGINIA BEACH, VA -- (Marketwired) -- 09/30/14 -- Global Holdings, Inc. (PINKSHEETS: GBHD) announces that it…

Continue Reading